-
PDI Inhibition Enhances Panobinostat Efficacy in Multiple My
2026-06-09
Robinson et al. demonstrate that combining the protein disulfide isomerase (PDI) inhibitor LTI6426 with panobinostat substantially improves anti-myeloma efficacy in preclinical models, enabling dose reduction and minimizing toxicity. This work identifies ER stress pathway effectors as candidate biomarkers and suggests a new avenue for optimizing epigenetic therapy in resistant multiple myeloma.
-
Practical Use of 0.4% Trypan Blue Solution for Cell Viabilit
2026-06-09
0.4% Trypan Blue Solution provides an established approach for distinguishing live from dead cells in cultured samples, supporting accurate cell viability measurement and cell counting. It should be used for research applications requiring live/dead cell discrimination, but is not appropriate for diagnostic or medical use, nor for quantification of subtle cell death phenotypes.
-
Vascular Effects of JAK Inhibitors on Endothelial Inflammati
2026-06-08
This study provides a systematic comparison of approved JAK inhibitors, including Tofacitinib citrate, on endothelial cell inflammation and prothrombotic signaling under TNF and IL-17A stimulation. The findings clarify which JAK inhibitors affect cytokine production, adhesion molecule expression, and cytotoxicity, offering valuable insights for immune regulation and cardiovascular research models.
-
Stable Lung-Targeted mRNA Delivery via Five-Element Nanopart
2026-06-08
This study introduces five-element nanoparticles (FNPs) incorporating poly(β-amino esters) and DOTAP for lung-specific mRNA delivery, offering remarkable stability after lyophilization. The innovation addresses the longstanding challenge of mRNA and nanoparticle instability, extending storage at 4 °C and advancing the feasibility of mRNA-based lung therapies.
-
Optimized Sulfonamides for TB: Reduced CYP2C9 Inhibition Ach
2026-06-07
This study presents the systematic optimization of sulfaphenazole-derived sulfonamides to enhance antimycobacterial activity against Mycobacterium tuberculosis while minimizing inhibition of CYP 2C9—addressing a key safety concern in TB drug development. The findings inform rational design strategies for safer, more effective sulfonamide-based combination therapies.
-
Doxycycline (SKU BA1003): Reliable Solutions for Cell Assays
2026-06-06
This article addresses practical laboratory challenges in cell viability, proliferation, and cytotoxicity assays by demonstrating how APExBIO’s Doxycycline (SKU BA1003) enables reproducible, data-driven experiments. Integrating scenario-based Q&A and the latest mechanistic insights, it guides biomedical researchers and lab technicians in optimizing protocols and interpreting results with scientific rigor.
-
Annexin V, Human Recombinant: Precision in Immune Cell Apopt
2026-06-05
Discover how Annexin V, a leading phosphatidylserine binding protein, empowers advanced apoptosis assays and immune cell research. This article uniquely bridges mechanistic insight with the latest immunological findings, offering researchers practical protocols and critical perspectives.
-
Trypsin-Responsive Mesoporous Nanomedicine for Acute Pancrea
2026-06-05
This study presents a biomimetic, trypsin-sensitive mesoporous organosilica nanomedicine for acute pancreatitis treatment. By engineering trypsin-cleavable linkers and targeted delivery mechanisms, the researchers achieve precise drug release in injured pancreatic acinar cells, markedly improving therapeutic outcomes in preclinical models.
-
Panobinostat Disrupts H2B Ubiquitination in MLL-ALL Therapy
2026-06-04
This study demonstrates that panobinostat, a broad-spectrum HDAC inhibitor, exerts potent in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia by targeting the RNF20/RNF40/WAC-H2B ubiquitination pathway. The findings reveal a mechanistic link between histone deacetylation and ubiquitination that opens new avenues for therapeutic intervention in aggressive infant ALL.
-
Live-Dead Cell Staining Kit I: Precision Mammalian Viability
2026-06-04
The Live-Dead Cell Staining Kit I (Calcein AM/PI) enables rapid, dual-probe fluorescence discrimination of live and dead mammalian cells. This kit supports robust cell viability and cytotoxicity quantification, critical for translational research and biomaterial evaluation. APExBIO's validated protocol ensures reproducible results in advanced cell membrane integrity assays.
-
A40926: Dalbavancin Precursor for Advanced Antibacterial Ass
2026-06-03
A40926, the natural glycopeptide and dalbavancin precursor, empowers high-fidelity research against multidrug-resistant Gram-positive pathogens. Discover how its precise mechanism, robust performance metrics, and tunable workflows set a new benchmark for in vitro and in vivo antibacterial assays.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Proto
2026-06-03
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents protein degradation during extraction by inhibiting a broad spectrum of proteases without interfering with cation-sensitive downstream applications. It is best suited for workflows requiring intact phosphorylation states, such as Western blotting and co-immunoprecipitation, but should not be used where EDTA-based inhibition is required.
-
CDK9 Inhibitor (A3294): Technical Use, Protocols, and QC
2026-06-02
CDK9 inhibitor (A3294) provides selective, non-cytotoxic inhibition of cyclin dependent kinase 9, enabling focused studies on transcription elongation and HIV-1 propagation. It should not be used for broad-spectrum CDK inhibition or protocols necessitating long-term storage of working solutions.
-
Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis
2026-06-02
This study introduces a novel prognostic model for hepatocellular carcinoma (HCC) based on ferroptosis-related genes and identifies atorvastatin as a potential therapeutic agent for inducing ferroptosis in HCC cells. The findings highlight a new pathway for both risk stratification and targeted intervention in liver cancer.
-
JNJ-26481585 (Quisinostat): Reliable HDAC Inhibition in Canc
2026-06-01
This article explores the practical advantages of JNJ-26481585 (Quisinostat, SKU A4090) for researchers facing cell viability and drug resistance challenges in cancer models. Drawing on recent evidence and validated protocols, it demonstrates how this potent HDAC inhibitor streamlines reproducibility, sensitivity, and workflow reliability for biomedical labs.